Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Bloomberg Customers

The Associated Press February 18, 2010, 8:27AM ET

Glaxo, XenoPort face additional FDA questions

GlaxoSmithKline and XenoPort Inc. said Thursday the Food and Drug Administration asked the company additional questions on their potential restless leg syndrome treatment Horizant.

The agency sent the companies a "Complete Response" letter and is concerned about the laboratory findings that showed pancreatic cell tumors in rats.

In November, the agency extended the review date to Feb. 9. in order to assess a risk evaluation and mitigation plan on the drug candidate.

The companies said they are assessing their next step in the regulatory process.

XenoPort is based in Santa Clara, Calif., and GlaxoSmithKline is headquartered in London.

BW Mall - Sponsored Links

Buy a link now!